RxDoctor Payments Data

Zafar Quader, MD

Gastroenterology · Springfield, ILNPI 1124013636

Payments from drug & device makers

$38,222in general payments, 2019–2025

Across 31 payments — averaging $1232.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$34K
  • AstraZeneca$4K
  • Johnson & Johnson$152
  • Madrigal Pharmaceuticals$149
  • Terumo Medical Corporation$137
  • Takeda Pharmaceuticals U.S.A., Inc.$55
  • plus $98 from 3 others
$1,770in research payments, 2019–2025

Across 6 payments — averaging $295.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Food & beverage$63995%
  • Education$325%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,222 in reported general payments places this provider in the 85th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$62,350
Medicare patients
240
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin23$79,677
DexilantDexlansoprazole12$3,934
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates32$1,996
Lubiprostone12$1,538
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg40$641
Pantoprazole Sodium75$531
Dicyclomine Hcl13$525
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$514
Omeprazole65$499
Famotidine51$321
Azathioprine19$311
Spironolactone21$212
Amitriptyline Hcl12$194
Metoclopramide Hcl16$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$55$3,93412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →